CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted Income from Continuing Operations of 3115000.0 for Q1 2026, up 90.26% on a QoQ basis from 31983000.0 in Q4 2025, and down 89.02% year-over-year from 28361988.95 in Q1 2025.
CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 3115000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 89.02% year-over-year to 3115000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35427000.0 (down 24.2% YoY) and the FY2025 annual result came in at 39936000.0, down 1.67% from the prior year.
- Income from Continuing Operations was 3115000.0 for Q1 2026 at CollPlant Biotechnologies, up from 31983000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5677000.0 in Q2 2023 and bottomed at 31983000.0 in Q4 2025.
- A 5-year average of 6552411.76 and a median of 3507000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 235.65% — and 2025, when it tumbled 138.07%.
- CollPlant Biotechnologies' Income from Continuing Operations stood at 27142000.0 in 2022, then climbed by 10.34% to 24335000.0 in 2023, then declined by 9.89% to 26741000.0 in 2024, then slipped by 19.6% to 31983000.0 in 2025, then jumped by 90.26% to 3115000.0 in 2026.
- Business Quant data shows CLGN's Income from Continuing Operations at 3115000.0 in Q1 2026, 31983000.0 in Q4 2025, and 3507000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | -31.98 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | -26.74 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | -24.34 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -27.14 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -227.59 Mn |
| Sep 30, 2021 | 71.91 Mn |
| Jun 30, 2021 | -2.98 Mn |